Genprex, Inc. 8-K

What Happened

• Genprex, Inc. announced that at its June 18, 2026 Annual Meeting stockholders approved an amended and restated 2018 Equity Incentive Plan. The Amended Equity Plan increases the pool of common stock authorized for awards by 1,850,000 shares (subject to adjustment for splits, dividends and similar events) and became effective upon shareholder approval. The plan term runs through April 15, 2036, and will continue for outstanding awards granted before that date.

Key Details

• Approval date: June 18, 2026 (2026 Annual Meeting).
• Additional shares authorized: 1,850,000 shares of common stock (adjustable for corporate actions).
• Plan term: Through April 15, 2036; remains in effect for awards outstanding after expiration.
• Full text of the Amended Equity Plan is filed as Exhibit 10.1 to the Form 8-K.

Why It Matters

• The increase expands the shares the company can grant as stock options, restricted stock, or other equity awards to employees, directors and consultants — a common tool for compensation and retention.
• Granting awards from the expanded pool can dilute existing shareholders over time if and when awards are issued and vested.
• Investors should note this is an authorization change (no immediate issuance specified); for material dilution or cost impact, watch future equity grant disclosures and the company’s compensation reports.